Navigation Links
Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
Date:8/21/2008

vascular Business. As previously announced, the Company completed the sale of its endovascular business to Spectranetics Corporation on May 30, 2008. This transaction included the sale of the ThromCat(R), QuickCat(TM) and SafeCross(R) products in consideration for $10 million in closing payments, an opportunity for up to an additional $14 million in various research and development and sales related milestones, as well as additional royalty payments based on future sales of the ThromCat(R) and SafeCross(R) products. The transaction included a manufacturing agreement, under which the Company will continue to manufacture the endovascular products for Spectranetics, and a research and development agreement, under which the Company will continue to perform defined development activities in pursuit of various FDA 510(k) approvals for next generation product approvals (please see the Company's news release dated May 13, 2008 for further information on the details of this transaction). The Company recognized a net loss of approximately $5.4 million (net of taxes of $2.7 million), or $0.44 per share tax-effected on the sale, which is presented within the Company's results of continuing operations for the quarter ended June 30, 2008. This loss does not include the benefit or expenses of achieving future milestones or royalties to be received under the transaction, which are expected to exceed the cost of accomplishing such milestones.

Share Repurchase Update. During the fourth quarter and the fiscal year ended June 30, 2008, the Company repurchased approximately 245,000 and 868,000 shares of its common stock, respectively for a total of $7.2 million and $24.4 million, respectively, with approximately $0.6 million remaining under the previously announced $25 million share repurchase program. On June 23, 2008, the Company announced that its board of directors had expanded its existing $25.0 million stock repurchase program, to provide for the repurchase of up to an addi
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
3. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
4. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
7. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arpida Reports Interim Results for Six Months to 30 June 2008
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , Oct 24, 2014 ... the "Epigenetics Market by Product , Research Area ... report to their offering. In ... the basis of products, research areas, and end users. ... this report are enzymes, instruments & consumables, kits, and ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... February 26 ScreenCancer AS, a Norwegian,company ... insurance,companies and individuals, today announced that it ... screening test to its European Cancer,Screening Program. ... a subsidiary of Quest Diagnostics Incorporated (NYSE: ...
... revolutionary Trusted LASIK Surgeons directory service and website at ... for consumers seeking to improve their vision and find ... chances of attaining 20-20 vision. What sets the ... process ensuring that only those who are among the ...
... 26 Syngenta announced today that the Board of ... Meeting on April 21, 2009, to name Stefan Borgas ... (45) is Chief Executive Officer of Lonza, one of ... life science industries, headquartered in Basel. Prior to joining ...
Cached Biology Technology:ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 3Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 2Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 3Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 4Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 5Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 6Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 7Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 8Syngenta Board Proposes Stefan Borgas to Become New Director 2
(Date:10/22/2014)... SAN JOSE, Calif. , Oct. 20, 2014 /PRNewswire/ ... with the United States Air Force Research Laboratory (AFRL), ... for Integrative Medicine (AzCIM) at the University of Arizona ... to receive research funding.  The AzCIM project,s goal is ... their ability to collect different volumes of sweat under ...
(Date:10/18/2014)... Among a group of 2,000 patients referred for ... a potential molecular diagnosis for 25 percent, including ... and new mutations contributing to disease, according to ... study is being released to coincide with the ... Whole-exome sequencing analyzes the exons or coding regions ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... an important discovery that raises doubts concerning the viability ... warming, a projected $100 billion venture. Research performed ... Journal of Geophysical Research, suggests that ocean fertilization may ... in the atmosphere, a major contributor to global warming. ...
... Researchers at the University of Illinois have developed ... treatment and drug delivery. The highly permeable and ... the functional water channel protein Aquaporin Z into ... currently in the form of vesicles, show significantly ...
... Maryland, USA; 29 November 2007 Galapagos NV (Euronext ... (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, ... treatments for cystic fibrosis. This new agreement between ... up to 5.5 million euros ($8.1 million U.S. dollars) ...
Cached Biology News:New research discredits $100B global warming 'fix' 2New research discredits $100B global warming 'fix' 3New research discredits $100B global warming 'fix' 4Researchers develop better membranes for water treatment, drug delivery 2Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration 2
... The Jouan RC10 series of vacuum ... product protection features allied to rapid and ... modules can be combined with oil-free or ... traps and a wide selection of rotors ...
... George Paxinos Affiliation: School of Psychology, The University ... Affiliation: Curtin University of Technology, Perth, Australia This ... of the rat brain. It is a ... revison and extension of the compact 3rd edition. ...
... kit. Includes configured Laptop PC with PCR ... MultiBlock satellite thermal Cycler (non-robotic). System ... software. Store/track run data. Gradient ... Outstanding uniformity. Advanced control algorithms for ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: